Stem cell co Mesoblast reports PhIII trial success in children with GVHD
An Australian stem cell company tackling a disease that often befalls blood cancer patients says it’s met the primary endpoint of a Phase III trial — and it’s expecting an accelerated FDA OK any day now.
The company, called Mesoblast $MESO, was testing its allogeneic mesenchymal stem cell product called remestemcel-L. The off-the-shelf therapy is meant to treat Graft Versus Host Disease, a condition that often arises in blood cancer patients who’ve had bone marrow transplants. After these transplants occur, donor cells have been known to attack the patient, causing GVHD, which activates an inflammatory response and potential tissue damage in the skin, gut, and liver. When the condition is severe and the patient doesn’t respond to steroids, it can be fatal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.